|

Study of Dextromethorphan in OCD and Related Disorders

RECRUITINGPhase 2Sponsored by Stanford University
Actively Recruiting
PhasePhase 2
SponsorStanford University
Started2022-01-20
Est. completion2026-04-01
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT04899687

Summary

The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.

Eligibility

Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria:

* Diagnosis of obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), illness anxiety disorder (IAD) or somatic symptom disorder (SSD)
* Living within California
* Capacity to provide informed consent

Exclusion Criteria:

* Current bipolar disorder or psychotic disorder
* Active moderate or severe substance use disorder, lifetime severe substance use disorder
* Pregnant or nursing women
* Use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior to study start
* Having commenced OCD-targeted exposure and response-prevention (ExRP) psychotherapy within 2 months of study start

Conditions5

AnxietyBody Dysmorphic DisordersIllness Anxiety DisorderObsessive-compulsive DisorderSomatic Symptom Disorder

Locations1 site

Stanford University
Stanford, California, 94304
Pavithra Makunda, MS650-723-4095ocdresearch@stanford.edu

Browse More Trials

Anxiety trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.